[Prevention of restenosis and of cardiac events after coronary angioplasty in diabetics].
Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis and clinical complications after coronary angioplasty, with or without stent, a main objective in the high risk diabetic population. The aim of the present paper is to describe the effects of the main pharmacological classes on the risk of restenosis, the need for new revascularisation procedures and the incidence of major clinical events (MACE: death, myocardial infarction, revascularisation). We will analyse successively the role of antiplatelet agents, omega 3 fatty acids, statins, anti-inflammatory compounds, immunomodulators, anti-oxidants and inhibitors of the renin-angiotensin system. Whenever possible, we will focus our attention on the results obtained in the diabetic population.
Nyssen
A
A
Université de Liège, Service de diabétologie, nutrition et maladies métaboliques et Unité de pharmacologie clinique, Département de médecine, CHU Sart Tilman, 4000 Liège, Belgique.
Legrand
V
V
Scheen
A J
AJ
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001530:Belgium / Q000453:epidemiology; D023903:Coronary Restenosis / Q000453:epidemiology / Q000517:prevention & control*; D003328:Coronary Thrombosis / Q000628:therapy*; D048909:Diabetes Complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D015994:Incidence; D015201:Meta-Analysis as Topic; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D015525:Fatty Acids, Omega-3; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D007155:Immunologic Factors; D010975:Platelet Aggregation Inhibitors